McKesson (MCK) Q1 2026: Specialty Pharma and GLP-1 Drive 25% U.S. Revenue Surge
Specialty pharmaceuticals and GLP-1 therapies powered a 25% revenue jump in McKesson’s U.S. segment, outpacing expectations and supporting a guidance raise. Strategic acquisitions in oncology and retina care are building durable growth platforms, while automation investments are lifting operating leverage. Portfolio rationalization accelerates as McKesson finalizes its exit from Europe, sharpening focus on high-value U.S. healthcare services.
Summary
- Specialty and GLP-1 Growth Accelerates: U.S. pharma segment surged as specialty and GLP-1 volumes expanded faster than the market.
- Strategic Acquisitions Expand Platform: Oncology and retina care deals deepen McKesson’s specialty footprint and recurring profit base.
- Operational Efficiency Drives Margin: Automation and cost discipline sharpen operating leverage, offsetting macro and portfolio headwinds.
Performance Analysis
McKesson delivered a standout first quarter, with consolidated revenues up 23% and U.S. pharmaceutical revenues climbing 25% year-over-year, fueled by robust prescription volume growth, specialty distribution, and a surge in GLP-1 medication sales. The U.S. pharmaceutical segment, which now accounts for over 90% of total revenue, saw operating profit rise 17%, reflecting both organic growth and contributions from recent acquisitions like Prism Vision, retina and ophthalmology platform, and Core Ventures, oncology MSO (Management Services Organization).
Prescription Technology Solutions (RxTS), McKesson’s digital medication access business, posted 16% revenue growth and 21% operating profit growth, driven by rising demand for access and affordability solutions, especially prior authorizations for GLP-1s. The medical-surgical business grew modestly, while international operations were flat after adjusting for Canadian divestitures. Operating expenses declined 1% despite higher U.S. pharma costs, as automation and portfolio rationalization offset inflation and integration costs.
- GLP-1 Revenue Expansion: GLP-1 sales hit $12.1 billion, up 38% YoY, now a major U.S. pharma driver.
- Acquisition-Fueled Profit Growth: Core Ventures and Prism Vision contributed 6-7% to U.S. pharma profit growth.
- Automation Yields Cost Leverage: Distribution centers achieved up to 90% automation, improving throughput and safety.
Free cash flow was negative $1.1 billion, reflecting heavy acquisition spend, but capital returns remained strong with $671 million returned to shareholders. Portfolio moves, including the Norway exit, further streamline the business and unlock value.
Executive Commentary
"We delivered record consolidated revenues... Three of our segments delivered double-digit growth in adjusted operating profit, reflecting continued momentum across the enterprise. We are executing against our growth commitments we outlined to our shareholders as demonstrated by these first quarter results."
Brian Tyler, Chief Executive Officer
"Across our pharmaceutical distribution network, we're strategically allocating capital to scale automation... These advancements are driving measurable operating leverage. We also recently opened our largest specialty distribution center... equipped with mobile autonomous robots, or COBOTs, that assist associates in the order fulfillment process."
Britt Villalon, Chief Financial Officer
Strategic Positioning
1. Oncology and Specialty Platform Expansion
McKesson’s oncology strategy is maturing into a flywheel, with the U.S. Oncology Network now reaching 3,300 providers across 700 sites. The acquisition of Core Ventures, integrating Florida Cancer Specialists, broadens access and data capabilities, reinforcing McKesson’s MSO model. Prism Vision extends this playbook to retina care, establishing a multi-therapy specialty platform with recurring, high-margin revenue.
2. Digital-First Access and Affordability
Prescription Technology Solutions (RxTS) is emerging as a key growth engine, connecting nearly one million providers and over 50,000 pharmacies. The segment’s scale in prior authorization and affordability solutions, especially for GLP-1s, positions McKesson as a critical intermediary in medication access, with digital infrastructure that is difficult for competitors to replicate.
3. Automation and Operational Discipline
Automation investments are transforming McKesson’s cost structure, with distribution centers reaching up to 90% automation and new specialty facilities leveraging robotics. These moves drive productivity, quality, and safety improvements, and provide resilience against labor and supply chain volatility. Operating expense leverage improved by 450 basis points YoY, supporting margin expansion even as the business scales.
4. Portfolio Simplification and Capital Allocation
The exit from Norway completes McKesson’s European divestiture, focusing the company on North American growth platforms. The planned spin-off of the medical-surgical segment will sharpen operational focus and unlock value, while disciplined M&A in high-growth verticals (oncology, retina, RxTS) aligns capital with durable profit pools.
5. Policy and Market Engagement
Leadership is actively engaging with policymakers on reimbursement and regulatory shifts, particularly around MFN (Most Favored Nation) and Medicaid changes. The company is positioning community-based care as essential for cost-effective, accessible healthcare, aiming to defend its specialty platform from adverse policy moves.
Key Considerations
McKesson’s first quarter reinforced its pivot to specialty and digital healthcare services, with organic growth, acquisitions, and automation converging to drive operating leverage. However, several dynamics warrant close investor attention as the year unfolds.
Key Considerations:
- GLP-1 Dependency: Growth in GLP-1 medications is a major profit driver, but volumes may fluctuate quarter to quarter as utilization and payer policies evolve.
- Integration Execution: Early gains from Core Ventures and Prism Vision are promising, but full synergy capture and platform scaling remain multi-quarter endeavors.
- Automation as a Margin Lever: Up to 90% automation in select facilities demonstrates progress, but scaling these gains enterprise-wide is a long-term process.
- Portfolio Rationalization: Exiting Norway and spinning off medical-surgical will concentrate the business, but also reduce diversification and may increase earnings volatility.
Risks
McKesson faces ongoing risks from regulatory changes, especially around drug pricing, reimbursement, and tariffs, which could impact specialty and core pharma margins. GLP-1 growth is not guaranteed, as payer policies and competitive launches may alter the demand trajectory. Integration risks from recent acquisitions and the complexity of large-scale automation initiatives could pressure near-term execution and cost savings realization.
Forward Outlook
For Q2 2026, McKesson guided to:
- Continued double-digit revenue and profit growth in U.S. pharmaceutical and RxTS segments
- GLP-1 and specialty volumes expected to vary by quarter but remain a key growth vector
For full-year 2026, management raised guidance:
- EPS range now $37.10 to $37.90, reflecting Norway exit and segment momentum
- Operating profit growth of 9% to 13%, revenue growth 11% to 15%
Management highlighted several factors that will shape results:
- GLP-1 demand and payer dynamics could drive upside or volatility in pharma and RxTS
- Integration of Core Ventures and Prism Vision will be a focus for synergy capture
Takeaways
McKesson’s Q1 results signal a business increasingly defined by specialty scale, digital connectivity, and operational discipline, with portfolio simplification sharpening focus and capital allocation. Investors should monitor the durability of GLP-1 and specialty growth, the pace of automation-driven margin gains, and the impact of further portfolio actions.
- Specialty and Digital Platform Strength: The company’s specialty and RxTS platforms are compounding growth, but integration and execution remain key to sustaining momentum.
- Margin and Cash Flow Leverage: Automation and cost discipline are offsetting macro headwinds, but ongoing investment is required to maintain competitive advantage.
- Watch for Policy and Portfolio Shifts: Regulatory volatility and the impact of portfolio simplification will shape risk and return in coming quarters.
Conclusion
McKesson’s specialty and digital healthcare strategy is delivering tangible results, with robust growth, expanding margins, and a more focused portfolio. The path ahead relies on continued execution in integration, automation, and regulatory navigation, as the company positions itself as a leading platform for specialty care and medication access.
Industry Read-Through
McKesson’s quarter underscores the accelerating shift toward specialty pharmaceuticals and digital medication access solutions across U.S. healthcare. The company’s automation and scale advantages highlight the increasing importance of operational efficiency in distribution, while its divestiture of European assets mirrors a broader trend among U.S. healthcare giants to focus on domestic, high-growth verticals. Competitors in distribution, specialty care, and digital health should note the margin and platform benefits of scale, automation, and integration— and the execution risk in complex, multi-segment healthcare businesses.